CLINICAL TRIALS PROFILE FOR SYNAREL
✉ Email this page to a colleague
All Clinical Trials for SYNAREL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02865681 ↗ | Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization | Completed | New Hope Fertility Center | N/A | 2016-07-01 | The purpose of the study is to evaluate the safety and efficacy of nasal gonadotropins (Menopur) in women undergoing IVF. The purpose of this study is also to report and monitor any and all side effects of the nasal Menopur. |
| NCT03991520 ↗ | Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms | Recruiting | University of California, San Diego | Early Phase 1 | 2020-06-16 | All current FDA approved medications to treat endometriosis pain including danazol, GnRH agonists (Lupron, Zoladex and Synarel), GnRH antagonist (elagolix) and depo-provera prevent or contradict pregnancy. Therefore women suffering from endometriosis and trying to conceive have no medical options apart from pain meds. The purpose of this pilot study is to determine whether the anti-inflammatory, IL-1 inhibitor (anakinra) reduces pelvic pain due to endometriosis without altering menstrual cycles, which is an indicator of ovulatory function. Anakinra is an FDA approved injectable medication for the treatment of rheumatoid arthritis that is pregnancy category B. |
| NCT05484193 ↗ | GnRH Agonist for Luteal Phase Support. | Active, not recruiting | Shaare Zedek Medical Center | N/A | 2020-06-08 | Objective To assess the the efficacy of luteal support with GnRH agonist in patients undergoing IVF in antagonist-based hcg triggered cycles compared with standard luteal support with progesterone. Design prospective randomized controled study Subjects Patients who underwent antagonist-based cycles performed in the "Shaare Zedek Medical Center" IVF clinic between 2020 and 2022 Intervention Intranasal GnRH-agonist or vaginal Progesterone for luteal support. Main outcome measures Pregnancy and clinical pregnancy rates, ohss. The study cohort included 150 patients who underwent 164 cycles. A total of 127 cycles were included. Of them, 64 were treated with GnRH-a and 63 with progesterone. Hypothesis: This RCT suggests that GnRH-a for luteal phase support is associated with a higher positive β-hCG pregnancy rate and clinical pregnancy rate, compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SYNAREL
Condition Name
Clinical Trial Locations for SYNAREL
Trials by Country
Clinical Trial Progress for SYNAREL
Clinical Trial Phase
Clinical Trial Sponsors for SYNAREL
Sponsor Name
